ES8206488A1 - Un procedimiento para preparar compuestos de purina y piri- midina - Google Patents

Un procedimiento para preparar compuestos de purina y piri- midina

Info

Publication number
ES8206488A1
ES8206488A1 ES505491A ES505491A ES8206488A1 ES 8206488 A1 ES8206488 A1 ES 8206488A1 ES 505491 A ES505491 A ES 505491A ES 505491 A ES505491 A ES 505491A ES 8206488 A1 ES8206488 A1 ES 8206488A1
Authority
ES
Spain
Prior art keywords
preparation
viral agents
guanine
guanine compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES505491A
Other languages
English (en)
Other versions
ES505491A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ens Bio Logicals Inc
Original Assignee
Ens Bio Logicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ens Bio Logicals Inc filed Critical Ens Bio Logicals Inc
Publication of ES505491A0 publication Critical patent/ES505491A0/es
Publication of ES8206488A1 publication Critical patent/ES8206488A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE COMPUESTOS DE PURINA Y PIRIMIDINA DE FORMULA (I), EN LA QUE R Y R'' SON RADICALES DISTINTOS DE HIDROGENO Y X PUEDE SER UNO DE VARIOS RADICALES DERIVADOS DE PIRIDINA O PIRIMIDINA. CONSISTE EN LA REACCION DEL COMPUESTO BASE DE PURINA O PIRIMIDINA, QUE TIENE AL MENOS UN GRUPO NH LIBRE O UN GRUPO NM, DONDE M PUEDE SER HALOGENO, SILILO SUSTITUIDO, ALCOHILO INFERIOR O UNA SAL DE MERCURIO, PLATA O ESTAÑO, CON UN COMPUESTO DE FORMULA (II), EN LA QUE HAL ES HALOGENO Y R2 Y R3 SON RADICALES DEL MISMO TIPO QUE R Y R'', SEGUIDA DE LA SUSTITUCION OPCIONAL DE LOS RADICALES R2 Y R3. LA REACCION SE LLEVA A CABO EN CADA CASO SIGUIENDO METODOS CONVENCIONALES. ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS POR SU ACTIVIDAD ANTIVIRAL.
ES505491A 1980-09-16 1981-09-15 Un procedimiento para preparar compuestos de purina y piri- midina Expired ES8206488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/187,631 US4347360A (en) 1980-09-16 1980-09-16 Ring open nucleoside analogues

Publications (2)

Publication Number Publication Date
ES505491A0 ES505491A0 (es) 1982-08-16
ES8206488A1 true ES8206488A1 (es) 1982-08-16

Family

ID=22689793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES505491A Expired ES8206488A1 (es) 1980-09-16 1981-09-15 Un procedimiento para preparar compuestos de purina y piri- midina

Country Status (20)

Country Link
US (1) US4347360A (es)
EP (2) EP0049072B1 (es)
JP (1) JPS5785373A (es)
AR (1) AR228756A1 (es)
AU (1) AU546840B2 (es)
CA (1) CA1305137C (es)
CS (1) CS258109B2 (es)
DE (1) DE3177156D1 (es)
DK (1) DK411081A (es)
ES (1) ES8206488A1 (es)
FI (1) FI72977C (es)
HK (1) HK82292A (es)
IE (1) IE58275B1 (es)
IL (1) IL63832A (es)
MX (1) MX7299E (es)
NO (1) NO161739C (es)
PT (1) PT73678B (es)
SG (1) SG74392G (es)
YU (1) YU224281A (es)
ZA (1) ZA816389B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508898A (en) * 1980-09-16 1985-04-02 Ogilvie Kelvin K Antiviral triazine compounds
US4501744A (en) * 1980-09-16 1985-02-26 Ens Bio Logicals Inc. Substituted-aza-cytosine compounds and anti-viral uses thereof
US5157120A (en) * 1980-09-16 1992-10-20 Syntex (U.S.A.) Inc. Guanine derivatives
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
US4423050A (en) * 1981-05-21 1983-12-27 Syntex (U.S.A.) Inc. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent
GB2104070B (en) * 1981-08-11 1985-08-14 Wellcome Found Purines
NZ201662A (en) * 1981-08-26 1986-07-11 Merck & Co Inc 9-(1,3-(and 2,3)-dihydroxy-1-(and 2)-propoxy-methyl)guanine derivatives and methods for their preparation
US5250535A (en) * 1982-02-01 1993-10-05 Syntex Inc. Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
US4609661A (en) * 1982-08-09 1986-09-02 Syntex (U.S.A.) Inc. Substituted 9-(1-O- or 3-O-monosubstituted or 1,3-di-O-substituted propoxymethyl)purines as antiviral agents
ZA836902B (en) * 1982-09-17 1985-05-29 Glaxo Group Ltd 5-halovinyl-2'-deoxyuridine derivatives
ES8507550A1 (es) * 1982-09-30 1985-09-16 Syntex Inc Procedimiento para la preparacion de 1-esteres monofosfato, 1,3-bis-esteres fosfato y esteres fosfato ciclico de 9-(1,3-dihidroxi-2-propoximetil)-guanina
US4609662A (en) * 1982-10-14 1986-09-02 Burroughs Wellcome Co. Method for using purine derivatives
US4462986A (en) * 1982-11-04 1984-07-31 Ens Bio Logicals, Inc. Synergistic anti-herpes compositions
US4565868A (en) * 1983-02-07 1986-01-21 Syntex (U.S.A.) Inc. Process for preparing guanine derivatives
US4460690A (en) * 1983-02-18 1984-07-17 Ens Bio Logicals Inc. Stimulation of viral growth rate
US4461757A (en) * 1983-02-23 1984-07-24 Ens Bio Logicals Inc. Dimethylaminomethylenated anti-herpes compounds
DE3490262T1 (de) * 1983-05-24 1985-11-28 Sri International, Menlo Park, Calif. Antivirus-Mittel
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
US4880820A (en) * 1983-06-24 1989-11-14 Merck & Co., Inc. Guanine derivatives
US4670424A (en) * 1983-09-19 1987-06-02 Merck & Co., Inc. Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
US4806642A (en) * 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
US4918219A (en) * 1983-10-31 1990-04-17 Warner-Lambert Company Glycerine derivatives
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
US4579849A (en) * 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
JPH0625061B2 (ja) * 1984-07-03 1994-04-06 ザ ウエルカム フアウンデ−シヨン リミテツド 抗ウイルス性化合物
EP0190123A1 (en) * 1984-07-20 1986-08-13 GAUNTT, Charles, O. Immunoregulatory and anti-viral compound
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
MY101126A (en) * 1985-12-13 1991-07-31 Beecham Group Plc Novel compounds
CA1330794C (en) * 1987-03-27 1994-07-19 Phillip Frost Anti-viral compounds, dosage forms and methods
US4863927A (en) * 1987-05-11 1989-09-05 Merck & Co., Inc. 1-(2-hydroxymethyl)cycloalkylmethyl)-5-substituted uracils
JPH0819111B2 (ja) * 1987-10-22 1996-02-28 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
EP0371139B1 (en) * 1988-03-31 1994-10-12 Mitsubishi Chemical Corporation 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
US5246931A (en) * 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
DE68922903T2 (de) * 1988-12-19 1995-11-23 Wellcome Found Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
GB8829571D0 (en) * 1988-12-19 1989-02-08 Wellcome Found Antiviral compounds
JPH02247191A (ja) * 1989-02-02 1990-10-02 Merck & Co Inc 抗レトロウイルス剤としてのプリンおよびピリミジン非環状ヌクレオシドの環状モノホスフエート類
DE3906357A1 (de) * 1989-03-01 1990-09-06 Boehringer Mannheim Gmbh Neue acyclische nucleosid-analoga, verfahren zu ihrer herstellung und verwendung dieser verbindungen als antivirale arzneimittel
DE4020481A1 (de) * 1990-06-27 1992-01-02 Hoechst Ag Verfahren zur herstellung von substituierten acyclischen nukleosiden und dabei auftretende zwischenprodukte
US5068119A (en) * 1990-09-28 1991-11-26 Nabisco Brands, Inc. Acid-hydrolyzable ester derivatives as low calorie fat mimetics
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
US6297226B1 (en) 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US6849735B1 (en) 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
WO2002004452A2 (en) 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
EP1966226B1 (en) * 2005-12-08 2010-11-10 K.U.Leuven Research & Development Azacytosine derivatives useful as antiviral agents
CA2644297A1 (en) * 2006-03-14 2007-09-20 Alt Solutions, Inc. Prevention and treatment of cancer and other diseases
CN103338754A (zh) 2010-12-10 2013-10-02 西格玛制药实验有限责任公司 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4146715A (en) * 1975-08-27 1979-03-27 Burroughs Wellcome Co. 2-amido-9-(2-acyloxyethoxymethyl)hypoxanthines
JPS52105195A (en) * 1976-03-01 1977-09-03 Wellcome Found Substituted purine
US4158056A (en) * 1978-07-13 1979-06-12 Eli Lilly And Company Antiviral method
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
GB2104070B (en) * 1981-08-11 1985-08-14 Wellcome Found Purines
NZ201662A (en) * 1981-08-26 1986-07-11 Merck & Co Inc 9-(1,3-(and 2,3)-dihydroxy-1-(and 2)-propoxy-methyl)guanine derivatives and methods for their preparation

Also Published As

Publication number Publication date
MX7299E (es) 1988-04-27
JPS5785373A (en) 1982-05-28
EP0049072A1 (en) 1982-04-07
US4347360B1 (es) 1985-10-08
AU7527381A (en) 1982-03-25
EP0243670B1 (en) 1992-07-22
IL63832A (en) 1985-06-30
NO161739B (no) 1989-06-12
FI72977C (fi) 1987-08-10
NO161739C (no) 1989-09-20
IE58275B1 (en) 1993-08-25
AR228756A1 (es) 1983-04-15
JPH052671B2 (es) 1993-01-13
IE812140L (en) 1982-03-16
ES505491A0 (es) 1982-08-16
HK82292A (en) 1992-10-30
PT73678A (en) 1981-10-01
NO813140L (no) 1982-03-17
YU224281A (en) 1983-10-31
DK411081A (da) 1982-03-17
DE3177156D1 (de) 1990-03-08
EP0049072B1 (en) 1990-01-31
CS258109B2 (en) 1988-07-15
IL63832A0 (en) 1981-12-31
EP0243670A1 (en) 1987-11-04
US4347360A (en) 1982-08-31
CA1305137C (en) 1992-07-14
ZA816389B (en) 1982-09-29
CS683281A2 (en) 1987-08-13
FI812857L (fi) 1982-03-17
FI72977B (fi) 1987-04-30
AU546840B2 (en) 1985-09-26
PT73678B (en) 1983-10-20
SG74392G (en) 1992-10-02

Similar Documents

Publication Publication Date Title
ES8206488A1 (es) Un procedimiento para preparar compuestos de purina y piri- midina
IL86040A0 (en) Acid stable dideoxynucleosides,their preparation and pharmaceutical compositions containing them
DE3160905D1 (en) Substituted imidazoles, their preparation and pharmaceutical compositions containing the same
IL69912A (en) Substituted 1-hydroxyethyltriazolyl derivatives,their preparation and their use as plant protection agents
FR2371453A1 (fr) Thiadiazolotriazinediones substituees, leur preparation et leur utilisation comme herbicides et comme agents antiviraux et antimicrobiens
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
GB2124077B (en) Immunomodulating agent
ES8802363A1 (es) Procedimiento para la fabricacion de derivados nucleosidos
LU91031I2 (en) Zaxem
DE3376421D1 (en) Analgesia-effecting 5-hydroxytryptophan derivatives
GR3007460T3 (es)
FR2387989A1 (fr) Analogues des alcaloides de l'ergot
ES8502703A1 (es) Un procedimiento para la preparacion de nuevos derivados de tienopirimidina.
ES2046641T3 (es) Composicion antitumoral.
MX170732B (es) Composicion de derivados de succinimida y su uso
ES8407322A1 (es) Procedimiento para la preparacion de 7 -aciltio-15,16-metilen-3-oxo-17 -pregna-1,4-dien-21,17-carbolactonas
ES2003086A6 (es) Procedimiento de obtencion de tienoquinolicinsulfonamidas
ES8203917A1 (es) Un procedimiento para la preparacion de un derivado de nu- cleosido de adenina
FR2498184B1 (es)
ES8301931A1 (es) Un procedimiento para la preparacion de nuevos imidazoles.
FR2446835A1 (fr) Octahydro-2h-pyrrolo(3,4-g)quinoleines utiles comme intermediaires
ES8600251A1 (es) Metodo de preparar nuevos 2-acilamino-5-feniletenilbencimidazoles
ATE23158T1 (de) Hexahydrodioxopyrimidine, ihre herstellung und verwendung.
FR2416223A1 (fr) Derives de phenylpyrol utilisables comme fongicides
ES2058182T3 (es) Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20020427